Baseline demographics and toxicity data
| Characteristic . | . |
|---|---|
| Age, y (median) | 63.5 (47-83) |
| Male sex | 23 |
| ECOG performance score | |
| 0 | 10 |
| 1 | 32 |
| Hemoglobin, g/dL (median) | 9.1 (6.0-10.0) |
| Neutrophils, ×109/L (median) | 4.9 (1.0-29.9) |
| Platelets, ×109/L (median) | 234 (104-1253) |
| Creatinine, mg/dL (median) | 1.0 (1.0-2.0) |
| Bilirubin, mg/dL (median) | 0.8 (0.4-2.0) |
| AST, U/L (median) | 12.8 (14-74) |
| Bone marrow | |
| Cellularity, % (median) | 80% (5-100) |
| Blasts, % (median) | 1% (0-14) |
| Splenomegaly | |
| Size, cm (median) | 21 (13-33) |
| RBC-transfusion dependent | 23 |
| Prior therapy | 13 |
| 2 or more prior therapies | 4 (10%) |
| Prior transplantation | 2 |
| Toxicity | Grade 3/4 |
| Hematologic | |
| Anemia | 20 |
| Thrombocytopenia | 7 |
| Neutropenia | 21 |
| Thrombosis | 3 |
| Nonhematologic | |
| Hepatic (LFTs) | 6 |
| Diarrhea | 1 |
| Cardiac | 2 |
| Electrolytes | 5 |
| Hypoxia | 1 |
| Characteristic . | . |
|---|---|
| Age, y (median) | 63.5 (47-83) |
| Male sex | 23 |
| ECOG performance score | |
| 0 | 10 |
| 1 | 32 |
| Hemoglobin, g/dL (median) | 9.1 (6.0-10.0) |
| Neutrophils, ×109/L (median) | 4.9 (1.0-29.9) |
| Platelets, ×109/L (median) | 234 (104-1253) |
| Creatinine, mg/dL (median) | 1.0 (1.0-2.0) |
| Bilirubin, mg/dL (median) | 0.8 (0.4-2.0) |
| AST, U/L (median) | 12.8 (14-74) |
| Bone marrow | |
| Cellularity, % (median) | 80% (5-100) |
| Blasts, % (median) | 1% (0-14) |
| Splenomegaly | |
| Size, cm (median) | 21 (13-33) |
| RBC-transfusion dependent | 23 |
| Prior therapy | 13 |
| 2 or more prior therapies | 4 (10%) |
| Prior transplantation | 2 |
| Toxicity | Grade 3/4 |
| Hematologic | |
| Anemia | 20 |
| Thrombocytopenia | 7 |
| Neutropenia | 21 |
| Thrombosis | 3 |
| Nonhematologic | |
| Hepatic (LFTs) | 6 |
| Diarrhea | 1 |
| Cardiac | 2 |
| Electrolytes | 5 |
| Hypoxia | 1 |
ECOG indicates Eastern Cooperative Group; AST, aspartate aminotransferase; RBC, red blood cell; and LFT, liver function test.